A-53930A and B, novel N-type Ca2+ channel blockers

被引:14
|
作者
Hisamoto, M
Inaoka, Y
Sakaida, Y
Kagazaki, T
Enokida, R
Okazaki, T
Haruyama, H
Kinoshita, T
Matsuda, K
机构
[1] Sankyo Co Ltd, Neurosci Res Labs, Shinagawa Ku, Tokyo 1408710, Japan
[2] Sankyo Co Ltd, Analyt & Metab Res Labs, Shinagawa Ku, Tokyo 1408710, Japan
[3] Sankyo Co Ltd, Biomed Res Labs, Iwaki, Fukushima 9718183, Japan
[4] Sankyo Co Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki 3050841, Japan
来源
JOURNAL OF ANTIBIOTICS | 1998年 / 51卷 / 07期
关键词
D O I
10.7164/antibiotics.51.607
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A-53930A, B and C, which inhibit N-type Ca2+ channels, were isolated from the culture broth of Streptomyces vinaceusdrappus SANK 62394. A-53930A and B were new compounds which contained a carbamoyl group on the 6-hydroxyl group of the D-gulosamine part of streptothricin. A-53930C was identical to streptothricin B. A-53930A, B and C inhibited [I-125]omega-conotoxin MVIIA binding to N-type Ca2+ channels (IC50 = 0.17, 0.091 and 0.071 mu M), but did not inhibit [H-3]PN200-110 binding to L-type Ca2+ channels (IC50> 50 mu M). These compounds also inhibited [H-3]norepinephrine release from chick cerebral cortex synaptosomes (IC50 = 91.0, 20.6 and 39.5 mu M), indicating these compounds selectively block N-type Ca2+ channels which are important for neurotransmitter release. It was also revealed that although A-53930C had antimicrobial activity against Gram-negative and -positive bacteria and fungi, A-53930A and B showed weak activity only against Gram-negative bacteria.
引用
收藏
页码:607 / 617
页数:11
相关论文
共 50 条
  • [31] A PKCε-ENH-channel complex specifically modulates N-type Ca2+ channels
    Maeno-Hikichi, Y
    Chang, SH
    Matsumura, K
    Lai, MZ
    Lin, H
    Nakagawa, N
    Kuroda, S
    Zhang, JF
    NATURE NEUROSCIENCE, 2003, 6 (05) : 468 - 475
  • [32] FUNCTIONAL-PROPERTIES OF THE PURIFIED N-TYPE CA2+ CHANNEL FROM RABBIT BRAIN
    DEWAARD, M
    WITCHER, DR
    CAMPBELL, KP
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1994, 269 (09) : 6716 - 6724
  • [33] Modulation of N-type Ca2+ channel current kinetics by PMA in rat sympathetic neurons
    Rafael E. García-Ferreiro
    Erick O. Hernández-Ochoa
    David E. García
    Pflügers Archiv, 2001, 442 : 848 - 858
  • [34] N-type Ca2+ channel blockade prevents sudden death in mice with heart failure
    Yamada, Yuko
    Kuwahara, Koichiro
    Kinoshita, Hideyuki
    Kuwabara, Yoshihiro
    Nakagawa, Yasuaki
    Harada, Masaki
    Yasuno, Shinji
    Minami, Takeya
    Usami, Satoshi
    Fujiwara, Masataka
    Murakami, Masao
    Ueshima, Kenji
    Nakao, Kazuwa
    ENDOCRINE JOURNAL, 2010, 57 : S566 - S566
  • [35] ANTINOCICEPTIVE EFFECTS OF CA2+ CHANNEL BLOCKERS
    MIRANDA, HF
    BUSTAMANTE, D
    KRAMER, V
    PELISSIER, T
    SAAVEDRA, H
    PAEILE, C
    FERNANDEZ, E
    PINARDI, G
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 217 (2-3) : 137 - 141
  • [36] Submit identification and reconstitution of the N-type Ca2+ channel complex purified from brain
    Witcher, D.R.
    De Waard, M.
    Sakamoto, J.
    Franzini-Armstrong, C.
    Pragnell, M.
    Kahl, S.D.
    Campbell, K.P.
    Science, 1993, 261 (5120)
  • [37] Postural hypotension following N-type Ca2+ channel blockade is amplified in experimental hypertension
    Wright, CE
    Hawkes, AL
    Angus, JA
    JOURNAL OF HYPERTENSION, 2000, 18 (01) : 65 - 73
  • [38] Modulation of N-type Ca2+ channel current kinetics by PMA in rat sympathetic neurons
    García-Ferreiro, RE
    Hernández-Ochoa, EO
    García, DE
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2001, 442 (06): : 848 - 858
  • [39] Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers
    Ku, Il Whea
    Cho, Sangwon
    Doddareddy, Munikumar Reddy
    Jang, Min Seok
    Keum, Gyochang
    Lee, Jung-Ha
    Chung, Bong Young
    Kim, Youseung
    Rhim, Hyewhon
    Kang, Soon Bang
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (19) : 5244 - 5248
  • [40] N-type calcium channel blockers in pain and stroke
    Cox, B
    Denyer, JC
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (10) : 1237 - 1250